Parnell Pharmaceuticals Holdings Ltd. announced the appointments of Edward Robb, DVM as Chief Scientific Officer, Andy Ferrigno as Vice President of Global Sales and Thomas E. Duley as a member of the Board of Directors and member of the Audit Committee. Dr. Robb brings significant R&D, clinical research and product development expertise in companion and production animal veterinary medicine to Parnell. Mr. Ferrigno joins with a successful, track record in animal health sales, having served as Vice President of Sales for the Novartis' US Companion Animal Business.

Mr. Duley is a partner in King & Spaulding's Silicon Valley Corporate Practice Group and has extensive experience in Life Science industry strategic partnerships, agreements and transactions. Robb is an accomplished global research and development executive and scientist with more than 30 years of experience in the animal health industry. Prior to joining Parnell, Dr. Robb held senior leadership positions at Boehringer-Ingelheim Vetmedica, Pfizer Animal Health, Pharmacia and Upjohn Animal Health and American Cyanamid, where he oversaw the global development of some of the industry's large production and companion animal veterinary medicines.

As Vice President of Research and Development at Boehringer-Ingleheim Vetmedica, Dr. Robb was responsible for all aspects of R&D, regulatory affairs and product development for pharmaceuticals and biologicals, and oversaw five research sites, a staff of 240 and an R&D budget in excess of $70 million. Dr. Robb will replace Robert P. Hunter as CSO, who will be pursuing opportunities outside of Parnell. Previously Andy held management positions of increasing responsibility at Novartis Animal Health for more than 20 years, across the sales, marketing and business development disciplines.

He directed all activities for the sales and commercial operations teams, including veterinary clinic sales, national account contracts, and commercial training and development. Prior, he was Head of Sales, Novartis Animal Health Australasia, where he was recognized for successfully growing topline revenue to unprecedented levels across the Australian and New Zealand companion animal and farm animal business segments. Prior, he was Senior Corporate Counsel for PDL BioPharma Inc., a fully integrated biopharmaceutical company.

Mr. Duley currently serves as an Adjunct Professor at U.C. In conjunction with Mr. Â Duley's appointment, Dr. Alan Bell will step down from his position as a member of the Audit Committee.